Revelation Biosciences (REVB) Current Assets (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Current Assets of $10.8 million for Q4 2025, up 64.67% year-over-year from $6.6 million in Q4 2024, and down 15.75% quarter-over-quarter from $12.8 million in Q3 2025.
Revelation Biosciences (REVB) Current Assets (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Current Assets for 6 consecutive years, with $10.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets rose 64.67% year-over-year to $10.8 million; the TTM figure through Dec 2025 stood at $10.8 million (up 64.67% YoY), while the FY2025 annual figure was $10.8 million, up 64.67% from the prior year.
- Current Assets fell to $10.8 million in Q4 2025 per REVB's latest filing, from $12.8 million in the prior quarter.
- Across five years, Current Assets topped out at $18.0 million in Q1 2023 and bottomed at $39083.0 in Q3 2021.
- Historically, Current Assets has averaged $8.0 million across 5 years, with a median of $6.6 million in 2024.
- Annual changes were most pronounced in 2021 — Current Assets tumbled 98.88% — and 2022, when it soared 16544.25%.
- Revelation Biosciences' Current Assets stood at $1.9 million in 2021, then surged by 183.11% to $5.4 million in 2022, then jumped by 124.4% to $12.1 million in 2023, then plunged by 45.95% to $6.6 million in 2024, then soared by 64.67% to $10.8 million in 2025.
- Business Quant data shows REVB's Current Assets at $10.8 million in Q4 2025, $12.8 million in Q3 2025, and $5.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Revelation Biosciences | 4.13 Mn | -7.37 Mn | - | 11.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.68 Mn |
| Dec 31, 2025 | 10.81 Mn |
| Sep 30, 2025 | 12.83 Mn |
| Jun 30, 2025 | 5.36 Mn |
| Mar 31, 2025 | 3.93 Mn |
| Dec 31, 2024 | 6.57 Mn |
| Sep 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 12.20 Mn |
| Mar 31, 2024 | 14.62 Mn |
| Dec 31, 2023 | 12.15 Mn |
| Sep 30, 2023 | 14.15 Mn |
| Jun 30, 2023 | 15.96 Mn |
| Mar 31, 2023 | 18.04 Mn |
| Dec 31, 2022 | 5.41 Mn |
| Sep 30, 2022 | 6.51 Mn |
| Jun 30, 2022 | 4.05 Mn |
| Mar 31, 2022 | 7.87 Mn |
| Dec 31, 2021 | 1.91 Mn |
| Sep 30, 2021 | 39,083.00 |
| Jun 30, 2021 | 373,640.00 |